The jury is still out on tiered provider networks. While effectiveness is frequently a criterion for including a specific drug on a preferred drug list, thus far, quality is only playing a small part in designing provider tiers.
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen